Fieldpoint Private Securities’s Pacira BioSciences PCRX Stock Holding History

Fieldpoint Private Securities’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1K	Hold	25	–	–	﹤0.01%	1387
2022 Q1	$2K	Hold	25	–	–	﹤0.01%	1499
2021 Q4	$2K	Sell	25 -30	-55%	-$1.65K	﹤0.01%	1495
2021 Q3	$3K	Sell	55 -35	-39%	-$2.02K	﹤0.01%	1396
2021 Q2	$5K	Sell	90 -10	-10%	-$633	﹤0.01%	1221
2021 Q1	$7K	Buy	100 +45	+82%	+$3.21K	﹤0.01%	1110
2020 Q4	$3K	Buy	+55	New	+$3.22K	﹤0.01%	1260

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Fieldpoint Private Securities's PCRX Position: Q2 2022 in Review

Fieldpoint Private Securities held its Pacira BioSciences (PCRX) position steady in Q2 2022 at 25 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1387.

Fieldpoint Private Securities first reported a position in PCRX in Q4 2020 and has held it in 7 quarters since. The position peaked at $7K in Q1 2021. 284 funds tracked by Wall St. Rank hold PCRX as of Q2 2022.

Fieldpoint Private Securities held 25 shares of Pacira BioSciences worth $1K as of Q2 2022.
Fieldpoint Private Securities left its Pacira BioSciences share count unchanged in Q2 2022.
Pacira BioSciences made up ﹤0.01% of Fieldpoint Private Securities's portfolio in Q2 2022, its #1387 holding.
Fieldpoint Private Securities first reported a position in Pacira BioSciences in Q4 2020 and has held it in 7 quarters since.
Fieldpoint Private Securities's Pacira BioSciences position peaked at $7K in Q1 2021.
284 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.